U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07157670) titled 'Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.' on Aug. 19.
Brief Summary: Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year. Conditioning and maintenance regimens carry a risk of both short- and long-term cardiotoxicity, leading to serious cardiovascular events including acute coronary syndrome (ACS), cardiac dysfunction, arrhythmias, pulmonary hypertension, and pericardial effusion. The pathophysiology of cardiotoxicity in ...